TRT on TikTok: separating real hypogonadism from hype

What did @dra_says actually say?

Dr. Ahmed, a UK-based GP, argues that testosterone replacement therapy is unfairly taboo and should be offered to more men. He lists symptoms of low testosterone, including low libido, increased body fat, muscle loss, fatigue, raised cholesterol, and even hot flushes. He calls TRT "generally very safe" with "very few side effects" and frames it as simply replacing a hormone men naturally produced more of when younger. He also says it is "easy to supplement and give and monitor."

The video is sympathetic in tone, clearly motivated by seeing patients suffer without adequate recognition or treatment. That is a legitimate clinical observation. But some of his framing around safety and simplicity deserves closer scrutiny.

Does the science back this up?

Partially, yes. The symptom cluster he describes is well-documented. The safety framing is where things get more complicated.

Low testosterone, or hypogonadism, is genuinely associated with reduced libido, changes in body composition, fatigue, mood disturbance, and metabolic changes including lipid shifts. A large cross-sectional study by Araujo et al. (2007, Journal of Clinical Endocrinology and Metabolism) estimated that 5.6% of men aged 30-79 in the US had symptomatic androgen deficiency. The condition is real and undertreated in some populations.

On safety, the picture is more nuanced. The TRAVERSE trial (Lincoff et al., 2023, New England Journal of Medicine), a large cardiovascular outcomes trial, found that testosterone therapy in men with hypogonadism did not significantly increase major adverse cardiovascular events compared to placebo. That is genuinely reassuring. However, the trial also confirmed elevated rates of pulmonary embolism, atrial fibrillation, and acute kidney injury in the testosterone group. Calling TRT a therapy with "very few side effects" glosses over a real risk profile that requires careful patient selection.

What did they get wrong or right?

He got the symptom list broadly right. He got the cardiovascular framing slightly too optimistic.

His description of low testosterone symptoms maps reasonably well onto clinical guidelines from the British Society for Sexual Medicine and the Endocrine Society. The mention of hot flushes in men is accurate and underappreciated. A review by Morales et al. (2010, European Urology) confirmed vasomotor symptoms can occur in men with hypogonadism, particularly post-orchidectomy, but also in age-related decline.

Where he oversimplifies is the safety and monitoring claim. TRT does require monitoring, but the monitoring itself is not simple. Haematocrit rises are a documented concern. Nilsson et al. (2021, The Aging Male) found polycythaemia rates requiring dose adjustment in a meaningful subset of patients on long-term TRT. Fertility suppression through HPG axis suppression is also a significant concern he does not mention, which matters for younger men. His claim that "we're just replacing a natural hormone" is partially true but skips the part where exogenous testosterone is not pharmacokinetically identical to endogenous production.

What should you actually know?

TRT is a legitimate medical treatment. It is not a wellness supplement. The distinction matters.

If you have symptoms consistent with hypogonadism, the right move is a full clinical assessment, not self-diagnosis from a TikTok video, however well-intentioned. In the UK, NICE does not have a specific guideline on TRT but the British Society for Sexual Medicine 2017 guidelines recommend two early morning testosterone measurements below the lab reference range alongside consistent symptoms before initiating treatment.

The TRAVERSE trial data (2023) is the most important recent development in this space. It largely reassured clinicians about cardiovascular risk but it was conducted in men aged 45-80 with pre-existing or high-risk cardiovascular disease. Extrapolating that safety data to all men seeking TRT is not straightforward.

If you are considering TRT through a private provider, ask about monitoring protocols, specifically haematocrit, PSA, and lipid panels. Ask what the plan is if you want to stop. Fertility preservation options should be discussed before starting. These are not scare tactics. They are standard clinical questions any responsible prescriber should welcome.